nesiritide
Trade name: natrecor
Approved
Aug 10, 2001
Nesiritide is the recombinant form of the 32 amino acid human B-type natriuretic peptide (BNP), which is normally produced by the ventricular myocardium. Human BNP binds to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells, leading to increased intracellular concentrations of guanosine 3'5'-cyclic monophosphate (cGMP) and smooth muscle cell relaxation. Cyclic GMP serves as a second messenger to dilate veins and arteries. Nesiritid was sold under brand name Natrecor for the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity. — NCATS
Clinical trial activity
69 trials · 48 clinical orgs · 1 marketing orgs
Earliest trial started Oct 1, 1996 (NCT00288730)
Timeline
Indications
Approved for
Studied for
- Acute Kidney Injury · Phase 3
- Cardiomyopathies · Phase 4
- Cardiopulmonary Bypass · Phase 3
- Cardio-Renal Syndrome · Phase 4
- Cardiovascular Diseases · Phase 4
- Coronary Artery Bypass · Phase 3
- Coronary Artery Disease · Phase 4
- Coronary Disease · Phase 3
- Death · Phase 3
- Dermatology · Phase 1
- Diabetes Mellitus · Phase 1
- Dyspnea · Phase 4
- Heart Defects, Congenital · Phase 2/Phase 3
- Heart Diseases · Phase 4
- Heart Failure · Phase 4
- Heart Failure, Diastolic · Phase 4
- Heart Transplantation · Phase 2
- Hyperinsulinism · Early Phase 1
- Hypertension · Phase 4
- Hypertension, Pulmonary · Phase 4
- Kidney Diseases · Phase 3
- Lung Diseases · Phase 4
- Melanoma · Phase 1
- Myocardial Infarction · Phase 2
- Myocardial Ischemia · Phase 3
- Neoplasms · Phase 4
- Obesity · Phase 1
- Pulmonary Edema · Phase 4
- Renal Insufficiency · Phase 4
- Signs and Symptoms · Phase 1/Phase 2
- Tetralogy of Fallot · Phase 2/Phase 3
- Thoracic Surgery · Phase 4
Mechanism of action
- Atrial natriuretic factorACTIVATOR
NPPA activator
NPR1 agonist
Approval history
- approvedAug 10, 2001
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaNatriuretic peptide ↗
- NCATSP7WI8UL647 ↗
- ChEMBLCHEMBL1201668 ↗
- WikipediaNesiritide ↗
Also known as
- bnp
- bnp
- brain natriuretic peptide
- brain natriuretic peptide
- brain natriuretic peptide 32
- brain natriuretic peptide 32
- brain natriuretic peptide-32
- b-type natriuretic peptide
- b-type natriuretic peptide
- human brain natriuretic factor-32
- human brain natriuretic peptide-32
- natiuretic peptides
- natrecor
- natrecor
- natrecor
- natriuretic peptide
- natriuretic peptides b
- natriuretic peptide type-b
- neseritide
- nesiritide
- nesiritide
- nesiritide
- nesiritide
- nesiritide
- nesiritide
- nesiritide
- nesiritide
- nesiritide
- nesiritide recombinant
- nesiritide recombinant
- nesiritide recombinant
- nesiritide recombinant
- nesritide
- recombinant b-type, natriuretic peptide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03738878 | Phase 4 | Nov 15, 2018 | Vanderbilt University |
| NCT03234751 | Phase 1 | Jul 13, 2017 | Translational Research Institute for Metabolism and Diabetes, Florida |
| NCT03207295 | N/A | Jul 5, 2017 | Chinese Academy of Medical Sciences, Tibet Kang Zhe Pharmaceutical Technology Co., Ltd |
| NCT02642523 | Early Phase 1 (Phase 1) | Aug 1, 2016 | Vanderbilt University |
| NCT02668536 | Phase 1 | Aug 1, 2016 | Yale University |
| NCT02742909 | Phase 4 | Dec 1, 2015 | China Medical University, Shengjing Hospital |
| NCT02608996 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2015 | Osaka University, Oslo Metropolitan University, University of Oslo |
| NCT02683174 | N/A | Aug 1, 2015 | NHS Lothian |
| NCT02269072 | N/A | Feb 1, 2015 | Harvard University |
| NCT01977859 | Phase 1 | Nov 1, 2013 | Advent Health, Sanford-Burnham Medical Research Institute, Translational Research Institute for Metabolism and Diabetes, Florida |
| NCT01941576 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2013 | Jiao Tong University |
| NCT01836809 | Phase 4 | Apr 1, 2013 | Virginia Commonwealth University |
| NCT01625403 | Phase 2 | Jul 1, 2012 | Jiao Tong University |
| NCT01637662 | N/A | Jul 1, 2012 | University of Copenhagen |
| NCT01514357 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2012 | Mayo Clinic |
| NCT02041663 | N/A | Feb 1, 2012 | University of Paris |
| NCT01544998 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2012 | Mayo Clinic, National Center for Research Resources (NCRR) |
| NCT01413542 | N/A | Nov 1, 2011 | Vanderbilt University |
| NCT01375153 | N/A | Nov 1, 2010 | University of Vienna |
| NCT01132846 | Phase 2 | Aug 1, 2010 | Duke University, Harvard University, National Heart, Lung, and Blood Institute (NHLBI) |